Skip to content

YI

111, Inc.

NASDAQ · CNHealthcareMedical - Pharmaceuticals
$3.94+8.54%

Price as of Jul 20, 2026

YI growth

111, Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue
-21.2%
EBITDA
EBIT
EPS
-22.6%
Free cash flow
Operating cash flow

Forward estimates

Revenue
EBITDA
EPS

Three-year CAGR

Revenue
-3.3%
EBITDA
-92.6%
EBIT
Net income
+74.0%
EPS
+1.3%
Free cash flow
-53.7%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.